FEMY Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.587

Open

0.572

VWAP

1.00

Vol

1.00M

Mkt Cap

32.00M

Low

0.525

Amount

555.00K

EV/EBITDA(TTM)

--

Total Shares

60.00M

EV

37.00M

EV/OCF(TTM)

--

P/S(TTM)

8.00

Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.

Show More

Events Timeline

(ET)

2026-01-13

09:10:00

Femasys Partners with Refuah Health Center to Launch FemaSeed

2025-12-31 (ET)

2025-12-31

16:40:00

Femasys Files to Sell 68.42M Shares of Common Stock

2025-12-18 (ET)

2025-12-18

09:20:00

Femasys Receives FDA 510(k) Clearance for FemVue Controlled Device

2025-11-25 (ET)

2025-11-25

09:23:02

PharmaCyte divests Femasys shares, anticipates cash reserves increasing to $20M

2025-11-10 (ET)

2025-11-10

09:10:50

Femasys Expands International Presence with Second European Order for FemBloc

2025-11-03 (ET)

2025-11-03

08:37:21

Femasys receives FDA clearance to proceed with the final phase of FemBloc trial.

2025-10-22 (ET)

2025-10-22

09:05:25

Femasys Launches Post-Market Surveillance Study for FemBloc

2025-10-16 (ET)

2025-10-16

14:09:42

Femasys Soars as Trump Anticipated to Broaden IVF Accessibility

News

an image of NASDAQ.COM

01-20NASDAQ.COM

Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%

an image of seekingalpha

01-14seekingalpha

Femasys (FEMY) Receives Nasdaq Approval for 180-Day Compliance Extension Until July 2026

an image of NASDAQ.COM

01-06NASDAQ.COM

Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement

an image of Benzinga

2025-12-24Benzinga

Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025

an image of NASDAQ.COM

2025-12-20NASDAQ.COM

Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO

an image of Newsfilter

2025-12-18Newsfilter

Femasys Receives FDA Clearance for FemVue Controlled Device

2 Analyst Rating

Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 4.75 USD with a low forecast of 3.00 USD and a high forecast of 6.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

4.75

High

6.50

Current: 0.000

Low

3.00

Averages

4.75

High

6.50

Laidlaw

Yale Jen

initiated

$6.50

AI Analysis

2025-11-20

Reason

Laidlaw

Yale Jen

Price Target

$6.50

AI Analysis

2025-11-20

initiated

Reason

Laidlaw analyst Yale Jen initiated coverage of Femasys with a Buy rating and $6.50 price target. Femasys is a development stage medical technology company focusing on two lead women healthcare products, FemaSeed and FemBloc, the analyst tells investors in a research note. The firm says FemaSeed is exploring a new and large market opportunity via gynecologist channel while FemBloc is heading to pivotal clinical study backed by "robust" prior clinical data.

JonesResearch

Buy

downgrade

$10 -> $6

2025-05-13

Reason

JonesResearch

Price Target

$10 -> $6

2025-05-13

downgrade

Buy

Reason

JonesResearch lowered the firm's price target on Femasys to $6 from $10 and keeps a Buy rating on the shares. The company reported Q1 earnings with no major updates to catalysts or its cash runway, the analyst tells investors in a research note. The firm remains positive on Femasys, but cut its price target to reflect the delayed launch of FemaSeed and an increase in share count from potential financing in 2025.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FEMY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Femasys Inc (FEMY.O) is -1.82, compared to its 5-year average forward P/E of -2.19. For a more detailed relative valuation and DCF analysis to assess Femasys Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-2.19

Current PE

-1.82

Overvalued PE

-0.57

Undervalued PE

-3.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

14.39

Current PS

4.82

Overvalued PS

32.88

Undervalued PS

-4.10

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks to buy below 1 $ now

Intellectia · 8 candidates

Market Cap: <= 2.00BPrice: <= $1.00Analyst Consensus: Moderate Buy, Strong BuyBeta: LowRisk, ModerateRiskWeekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

Strive Inc

1.00B

TRX Gold Corp

271.00M

BRC Inc

247.00M

Mereo BioPharma Group PLC

84.00M

Ocean Power Technologies Inc

78.00M

Plus Therapeutics Inc

52.00M

Whales Holding FEMY

Trading Trends

People Also Watch

Frequently Asked Questions

What is Femasys Inc (FEMY) stock price today?

The current price of FEMY is 0.5487 USD — it has decreased -6.64 % in the last trading day.

What is Femasys Inc (FEMY)'s business?

Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.

What is the price predicton of FEMY Stock?

Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is4.75 USD with a low forecast of 3.00 USD and a high forecast of 6.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Femasys Inc (FEMY)'s revenue for the last quarter?

Femasys Inc revenue for the last quarter amounts to 729.00K USD, increased 31.44 % YoY.

What is Femasys Inc (FEMY)'s earnings per share (EPS) for the last quarter?

Femasys Inc. EPS for the last quarter amounts to -0.10 USD, decreased -58.33 % YoY.

How many employees does Femasys Inc (FEMY). have?

Femasys Inc (FEMY) has 69 emplpoyees as of January 30 2026.

What is Femasys Inc (FEMY) market cap?

Today FEMY has the market capitalization of 32.00M USD.